-
9321
Permanent Ad-lib Feeders Decrease the Survival of Wintering Great Tits (<i>Parus major</i>)
Published 2023-05-01Get full text
Article -
9322
-
9323
A Unique Crustacean-Based Chitin Platform to Reduce Self-Aggregation of Polysaccharide Nanofibers
Published 2022-10-01Get full text
Article -
9324
-
9325
-
9326
-
9327
-
9328
Environmental Life Cycle Assessment of Premium and Ultra Hygiene Tissue Products in the United States
Published 2023-04-01Get full text
Article -
9329
-
9330
Are starch-based materials more eco-friendly than fossil-based? A critical assessment
Published 2024-06-01Get full text
Article -
9331
-
9332
Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma
Published 2018-05-01“…Ronald M Sánchez-Avila,1 Jesus Merayo-Lloves,1 Maria Laura Fernández,1,2 Luis Alberto Rodríguez-Gutiérrez,1 Pedro Pablo Rodríguez-Calvo,1 Andres Fernández-Vega Cueto,1 Francisco Muruzabal,3,4 Gorka Orive,3–6 Eduardo Anitua3,4 1University Institute Fernández-Vega, Ophthalmological Research Foundation, University of Oviedo, Oviedo, Spain; 2Quilmes Eye Center, Buenos Aires, Argentina; 3University Institute for Regenerative Medicine and Oral Implantology (UIRMI), University of the Basque Country, Eduardo Anitua Foundation, Vitoria, Spain; 4Biotechnology Institute (BTI), Vitoria, Spain; 5Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; 6Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Vitoria, Spain Purpose: To evaluate the efficacy and safety of plasma rich in growth factors (PRGF) eye drops in patients with glaucoma with secondary ocular surface disorders (OSDs) due to surgeries and topical hypotensive drugs use. …”
Get full text
Article -
9333
-
9334
The most common European HINT1 neuropathy variant phenotype and its case studies
Published 2023-02-01Get full text
Article -
9335
Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival
Published 2023-02-01Get full text
Article